Table 3.

Main challenges facing PSC-derived therapies for SCI.

1. PSC’ intrinsic tumorigenic potential

2. Immunogenicity problems associated with the allogeneic use (immunosuppressants required)

3. Optimal cell type, dose, route, timing and immunosuppression regime for each condition still not known

4. Lack of efficacy in some conditions, especially in chronic SCI

5. High production costs